| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 468 |
| 1 | CYCLOPHOSPHAMIDE | 408 |
| 2 | CYCLOPHOSPHAMIDE FOR INJECTION | 408 |
| 3 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 408 |
| 4 | DOXORUBICIN | 364 |
| 5 | ETOPOSIDE | 292 |
| 6 | PREDNISONE | 280 |
| 7 | DEXAMETHASONE | 250 |
| 8 | DEXAMETHASONE 1.5 MG | 250 |
| 9 | CYTARABINE | 235 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | EPCORITAMAB-BYSP | 235 | 0.1756 |
| 1 | HEXYLRESORCINOL | 1 | 0.0455 |
| 2 | CASPOFUNGIN ACETATE | 48 | 0.0303 |
| 3 | RITUXIMAB AND HYALURONIDASE | 12 | 0.0265 |
| 4 | LONCASTUXIMAB TESIRINE | 6 | 0.0146 |
| 5 | POLATUZUMAB VEDOTIN | 114 | 0.0112 |
| 6 | IFOSFAMIDE FOR INJECTION | 163 | 0.0076 |
| 7 | GLOFITAMAB | 17 | 0.0063 |
| 8 | ALBUMIN HUMAN | 29 | 0.0058 |
| 9 | SELINEXOR | 51 | 0.0058 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 559 |
| 1 | CD20-directed Cytolytic Antibody [EPC] | 476 |
| 2 | Alkylating Drug [EPC] | 440 |
| 3 | Platinum-based Drug [EPC] | 370 |
| 4 | Topoisomerase Inhibitor [EPC] | 292 |
| 5 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 252 |
| 6 | Nucleoside Metabolic Inhibitor [EPC] | 235 |
| 7 | Folate Analog Metabolic Inhibitor [EPC] | 87 |
| 8 | Thalidomide Analog [EPC] | 85 |
| 9 | Leukocyte Growth Factor [EPC] | 63 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 252 | 0.0623 |
| 1 | Endoglycosidase [EPC] | 19 | 0.0103 |
| 2 | Nuclear Export Inhibitor [EPC] | 51 | 0.0058 |
| 3 | Macrolide Antibacterial [EPC] | 4 | 0.0040 |
| 4 | Topoisomerase Inhibitor [EPC] | 292 | 0.0038 |
| 5 | CD19-directed Chimeric Antigen Receptor [EPC] | 34 | 0.0033 |
| 6 | Alkylating Drug [EPC] | 440 | 0.0018 |
| 7 | CD20-directed Cytolytic Antibody [EPC] | 476 | 0.0015 |
| 8 | Platinum-based Drug [EPC] | 370 | 0.0014 |
| 9 | Lipopeptide Antibacterial [EPC] | 10 | 0.0011 |